A Dosing Algorithm for Erythropoietin Alpha in Older Adults with Heart Failure and a Preserved Ejection Fraction

Cardiovascular Therapeutics

Volumn 31, Issue 2, 2013, Pages 92-99

  Altincatal, Arman ^a   MacArthur, Robert B ^a   Teruya, Sergio ^a   Helmke, Stephen ^a   Maurer, Mathew S ^a  

^a NewYork Presbyterian Hospital   (United States)

Author keywords

Anemia; Dosing; Epoeitin alfa; Heart failure

Indexed keywords

DIURETIC AGENT; HEMOGLOBIN; PLACEBO; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE CALCULATION; DOSE RESPONSE; DRUG DOSE REDUCTION; FEMALE; HEART EJECTION FRACTION; HEART FAILURE; HEMOGLOBIN DETERMINATION; HUMAN; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; WEIGHT CHANGE;

AGED; AGED, 80 AND OVER; ALGORITHMS; ANEMIA; BIOLOGICAL MARKERS; BLOOD PRESSURE; BLOOD VOLUME; CONFOUNDING FACTORS (EPIDEMIOLOGY); DIURETICS; DRUG ADMINISTRATION SCHEDULE; DRUG DOSAGE CALCULATIONS; ERYTHROPOIETIN; FEMALE; HEART FAILURE; HEMATINICS; HEMOGLOBINS; HUMANS; MALE; MULTIVARIATE ANALYSIS; NEW YORK CITY; RECOMBINANT PROTEINS; SINGLE-BLIND METHOD; STROKE VOLUME; TIME FACTORS; TREATMENT OUTCOME;

EID: 84875806967     PISSN: 17555914     EISSN: 17555922     Source Type: Journal    
DOI: 10.1111/j.1755-5922.2011.00295.x     Document Type: Article

References (39)

1. Cohen RS, Mubashir A, Wajahat R, Mani S, Hummel S, Maurer MS. The cardio-renalanemia syndrome in elderly subjects with heart failure and a normal ejection fraction: A comparison with heart failure and low ejection fraction. Congest Heart Fail 2006;12:186-191.
2. He SW, Wang LX. The impact of anemia on the prognosis of chronic heart failure: A meta-analysis and systemic review. Congest Heart Fail 2009;15:123-130.
3. Groenveld HF, Januzzi JL, Damman K, van Wijngaarden J, Hillege HL, van Veldhuisen DJ, van der Meer P. Anemia and mortality in heart failure patients a systematic review and meta-analysis. J Am Coll Cardiol 2008;52:818-827.
4. McMurray JJ, Anand IS, Diaz R, et al. Design of the Reduction of Events with Darbepoetin alfa in Heart Failure (RED-HF): A Phase III, anaemia correction, morbidity-mortality trial. Eur J Heart Fail 2009;11:795-801.
5. Ngo K, Kotecha D, Walters JA, Manzano L, Palazzuoli A, van Veldhuisen DJ, Flather M. Erythropoiesis-stimulating agents for anaemia in chronic heart failure patients. Cochrane Database Syst Rev 2010;(1):CD007613.
6. van der Meer P, Groenveld HF, Januzzi JL, Jr., van Veldhuisen DJ. Erythropoietin treatment in patients with chronic heart failure: A meta-analysis. Heart 2009;95:1309-1314.
7. Pfeffer MA, Burdmann EA, Chen CY, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009;361:2019-2032.
8. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006;355:2085-2098.
9. Szczech LA, Barnhart HX, Sapp S, et al. A secondary analysis of the CHOIR trial shows that comorbid conditions differentially affect outcomes during anemia treatment. Kidney Int 2010;77:239-246.
10. Unger EF, Thompson AM, Blank MJ, Temple R. Erythropoiesis-stimulating agents-time for a reevaluation. N Engl J Med 2010;362:189-192.
11. Schocken DD, Arrieta MI, Leaverton PE, Ross EA. Prevalence and mortality rate of congestive heart failure in the United States. J Am Coll Cardiol 1992;20:301-306.
12. Patwardhan VN. Nutritional anemias-WHO research program. Early developments and progress report of collaborative studies. Am J Clin Nutr 1966;19:63-71.
13. Cohen RS, Karlin P, Yushak M, Mancini D, Maurer MS. The effect of erythropoietin on exercise capacity, left ventricular remodeling, pressure-volume relationships, and quality of life in older patients with anemia and heart failure with preserved ejection fraction. Congest Heart Fail 2010;16:96-103.
14. Abramov D, Cohen RS, Katz SD, Mancini D, Maurer MS. Comparison of blood volume characteristics in anemic patients with low versus preserved left ventricular ejection fractions. Am J Cardiol 2008;102:1069-1072.
15. Feldschuh J, Katz S. The importance of correct norms in blood volume measurement. Am J Med Sci 2007;334:41-46.
16. Besarab A. Optimizing anaemia management with subcutaneous administration of epoetin. Nephrol Dial Transplant 2005;20(Suppl 6):vi10-vi15.
17. Locatelli F, Villa G, Messa P, et al. Efficacy and safety of once-weekly intravenous epoetin alfa in maintaining hemoglobin levels in hemodialysis patients. J Nephrol 2008;21:412-420.
18. Pussell BA, Walker R. Dose of epoetin alfa used in haemodialysis patients when switching from subcutaneous to intravenous administration. Nephrology (Carlton) 2007;12:120-125.
19. Pergola PE, Gartenberg G, Fu M, Sun S, Wolfson M, Bowers P. A randomized controlled study comparing once-weekly to every-2-week and every-4-week dosing of epoetin alfa in CKD patients with anemia. Clin J Am Soc Nephrol 2010;5:598-606.
20. Barre P, Reichel H, Suranyi MG, Barth C. Efficacy of once-weekly epoetin alfa. Clin Nephrol 2004;62:440-448.
21. Benz R, Schmidt R, Kelly K, Wolfson M. Epoetin alfa once every 2 weeks is effective for initiation of treatment of anemia of chronic kidney disease. Clin J Am Soc Nephrol 2007;2:215-221.
22. Grossman HA, Goon B, Bowers P, Leitz G. Once-weekly epoetin alfa dosing is as effective as three times-weekly dosing in increasing hemoglobin levels and is associated with improved quality of life in anemic HIV-infected patients. J Acquir Immune Defic Syndr 2003;34:368-378.
23. Palazzuoli A, Silverberg DS, Calabro A, et al. Beta-erythropoietin effects on ventricular remodeling, left and right systolic function, pulmonary pressure, and hospitalizations in patients affected with heart failure and anemia. J Cardiovasc Pharmacol 2009;53:462-467.
24. Mancini DM, Katz SD, Lang CC, LaManca J, Hudaihed A, Androne AS. Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation 2003;107:294-299.
25. Palazzuoli A, Quatrini I, Calabro A, et al. Anemia correction by erythropoietin reduces BNP levels, hospitalization rate, and NYHA class in patients with cardio-renal anemia syndrome. Clin Exp Med 2010;11:43-48.
26. Szczech LA, Barnhart HX, Inrig JK, et al. Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int 2008;74:791-798.
27. Singh AK. The controversy surrounding hemoglobin and erythropoiesis-stimulating agents: What should we do now?Am J Kidney Dis 2008;52(Suppl):S5-S13.
28. Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998;339:584-590.
29. Drueke TB, Locatelli F, Clyne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006;355:2071-2084.
30. Regidor DL, Kopple JD, Kovesdy CP, et al. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol 2006;17:1181-1191.
31. Solomon SD, Uno H, Lewis EF, et al. Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med 2010;363:1146-1155.
32. Lundby C, Thomsen JJ, Boushel R, Koskolou M, Warberg J, Calbet JA, Robach P. Erythropoietin treatment elevates haemoglobin concentration by increasing red cell volume and depressing plasma volume. J Physiol 2007;578(Pt 1):309-314.
33. Fogh-Andersen N, Eidemak I, Lokkegaard H, Levin Nielsen S. Changes in blood and plasma volume during treatment with recombinant human erythropoietin. Scand J Clin Lab Invest Suppl 1993;214:61-65.
34. Olsen NV, Aachmann-Andersen NJ, Oturai P, et al. Recombinant human erythropoietin in humans down-regulates proximal renal tubular reabsorption and causes a fall in glomerular filtration rate. J Physiol 2010;589(Pt 6):1273-1281.
35. Adlbrecht C, Kommata S, Hulsmann M, et al. Chronic heart failure leads to an expanded plasma volume and pseudoanaemia, but does not lead to a reduction in the body's red cell volume. Eur Heart J 2008;29:2343-2350.
36. Yamakado M, Umezu M, Nagano M, Tagawa H. Mechanisms of hypertension induced by erythropoietin in patients on hemodialysis. Clin Invest Med 1991;14:623-629.
37. Jones MA, Kingswood JC, Dallyn PE, Andrew M, Cheetham A, Burwood R, Sharpstone P. Changes in diurnal blood pressure variation and red cell and plasma volumes in patients with renal failure who develop erythropoietininduced hypertension. Clin Nephrol 1995;44:193-200.
38. Raine AE, Roger SD. Effects of erythropoietin on blood pressure. Am J Kidney Dis 1991;18(Suppl 1):76-83.
39. Imai Y, Sekino H, Fujikura Y, et al. Pressor effect of recombinant human erythropoietin: Results of ambulatory blood pressure monitoring and home blood pressure measurements. Clin Exp Hypertens 1995;17:485-506.